GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, alveolar soft part sarcoma, benign urinary system neoplasm, breast disorder, breast neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, myomatous neoplasm, neoplasm, renal cell carcinoma, sarcoma, skin disorder, triple-negative breast carcinoma, urinary system disorder	Recruiting	Phase 1	2026-10-08		NCT07297667

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
BioCanRx	1
Canadian Cancer Trials Group	73
Canadian Institutes of Health Research (CIHR)	339
University of Calgary	238

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Arthur J.E. Child Comprehensive Cancer Centre	Calgary	Canada	45
The Research Institute of the McGill University	Montreal	Canada	10
University Health Network	Toronto	Canada	52